top of page
Crystal Spheres

PIPELINE
NEEDLE-FREE BIOLOGIC DELIVERY

Our Pipeline

We are advancing a pipeline of transdermal biologic and peptide therapies targeting high-value indications in metabolic disease, endocrinology, and age-related conditions such as obesity and sarcopenia.

 

Each program leverages our HeroPatch™ microneedle platform to enable needle-free, tunable delivery of complex molecules. By tailoring release rates to each molecule’s ideal pharmacokinetic profile, we aim to optimize therapeutic outcomes and address major unmet needs with more accessible, patient-friendly solutions.

Product
Candidate

PK/PD Optimization

IND
Enabling

Phase I

Phase II

Phase III

ANN-101
GLP-1 RA

Indication: Obesity | Stage: IND-enabling to begin Phase I Study Q1 2026

ANN-101 is a once-weekly GLP-1 receptor agonist transdermal patch. Preclinical studies demonstrated multi-milligram delivery of GLP-1, exceeding that of subcutaneous semaglutide injections, without the need for cold-chain logistics. ANN-101 has the potential to minimize gastrointestinal side effects, enhance adherence, and expand global access to obesity therapies. 

ANN-102
APJ RA

Indication: Sarcopenia | Stage: PK/PD Optimization

ANN-102 is a first-in-class transdermal therapy targeting the APJ receptor to combat muscle loss associated with aging. Daily administration of the APJ-RA via Anodyne’s HeroPatch™ system showed equivalent efficacy to injections in preclinical models, significantly improving muscle strength. This innovation opens a path to safe, convenient interventions for sarcopenia—a growing unmet need in an aging population.

ANN-103
GLP-1 RA + APJ RA

Indication: Sarcopenic Obesity | Stage: PK/PD Optimization

ANN-103 is a combination patch delivering GLP-1 and APJ receptor agonists to promote fat loss while preserving muscle mass. It addresses the critical drawback of standalone GLP-1 therapies, which may cause up to 40% of weight loss from lean body mass. ANN-103 offers a dual-action approach to combat sarcopenic obesity, advancing both obesity care and healthy aging.

Undisclosed
mAb

Indication: Undisclosed | Stage: PK/PD Optimization
 

ANN-101 | once-weekly GLP-1 patch for obesity
ANN-102 | APJ RA patch for sarcopenia
ANN 103 | Combination Patch GLP-1/APJ RA for sarcopenic obesity
bottom of page